Table 4 Association of heparin dosage and mortality.

From: Effect of early prophylactic heparin use on prognosis in critically ill patients with acute pancreatitis: a retrospective cohort study

Mortality

28-day mortality

90-day mortality

In-hospital mortality

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Model I

 0 dose

References

     

 2 doses

0.57 (0.34–0.97)

0.037

0.62 (0.42–0.92)

0.017

0.47 (0.27–0.84)

0.011

 3 doses

0.64 (0.42–0.98)

0.042

0.64 (0.47–0.89)

0.008

0.65 (0.41–1.01)

0.057

Model II

 0 dose

References

     

 2 doses

0.50 (0.31–0.90)

0.019

0.58 (0.40–0.86)

0.007

0.44 (0.24–0.80)

0.007

 3 doses

0.60 (0.40–0.95)

0.029

0.60 (0.45–0.87)

0.005

0.61 (0.38–0.96)

0.034

Model III

 0 dose

References

     

 2 doses

0.56 (0.31–0.99)

0.049

0.58 (0.40–0.86)

0.011

0.40 (0.19–0.87)

0.021

 3 doses

0.66 (0.41–1.07)

0.095

0.70 (0.49–1.01)

0.058

0.83 (0.44–1.56)

0.561

  1. Model I: crude.
  2. Model II: adjusted for age, gender, ethnicity, weight.
  3. Model III: adjusted for model II, covariates, ventilation, CRRT, vasopressin, malignancy, renal failure, heart failure, platelets, WBC, RBC, AG, BUN, creatinine, INR, MAP, respirator rate, temperature, SOFA, SAPS II, CCI.
Back to article page